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Lymphangioleiomyomatosis (LAM) is a rare lung disease affecting women. Following case
reports that pregnancy exacerbates LAM, patients are frequently advised to avoid pregnancy.
Our objective was to determine pregnancy and health outcomes in LAM to provide better
evidence with which to council patients contemplating pregnancy.
We surveyed 328 women with LAM regarding pregnancy outcomes, pulmonary function,
subjective and psychological functioning, quality of life, dyspnoea and fatigue.
Amongst childless women the main reason not to attempt pregnancy was based on concerns
about potential effects of pregnancy on LAM. Almost two thirds of patients had been pregnant,
the majority before LAM was diagnosed, in whom pregnancy outcome was generally favour-
able. Women diagnosed with LAM (nZ 15) during pregnancy had high rates of pneumothorax
(67%), miscarriage (7%) and premature birth (47%). The group diagnosed with LAM before or
during pregnancy (nZ 12) had lower mean FEV1, FVC and DLCO after pregnancy compared
with those diagnosed following pregnancy or never pregnant. There were no differences in
subjective or psychological functioning, quality of life, dyspnoea or fatigue scores between
groups. In newly diagnosed LAM patients there was a high incidence of premature birth and
pneumothorax. These adverse outcomes may be a marker of aggressive LAM.
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Lymphangioleiomyomatosis (LAM) is a rare disease of women
which affects the lungs and lymphatics. Clinical symptoms
include shortness of breath with exertion, pneumothorax,
and fatigue leading to debilitating respiratory impairment
in many cases.1,2 Angiomyolipoma, a benign kidney tumour,
is also present in up to 50% of patients with LAM.3 LAM is rare.
Pregnancy experiences in LAM 767in the general population (sporadic LAM) but is common
in women with tuberous sclerosis complex (TSC-LAM). Both
TSC and LAM are linked to mutations in the TSC1 and TSC2.4,5
The disease is generally progressive resulting in
increasing airflow obstruction and impairment of gas
transfer although clinical progression and rate of decline of
lung function vary markedly between patients.6e8 Although
no prospective data are available, retrospective 10 year
survival from the onset of symptoms is between 71 and
91%.9,10 There is no proven treatment for LAM and patients
generally receive supportive care including bronchodila-
tors, supplemental oxygen and lung transplantation as
appropriate.
Since LAM almost exclusively affects women and can be
exacerbated by exogenous oestrogen it has been assumed
that oestrogen is associated with disease progression and
that increased oestrogen levels during pregnancy might
exacerbate the disease. A number of case reports have
described LAM presenting or worsening during pregnan-
cy.11e13 A small series has shown that although some
women have uncomplicated pregnancies, overall, preg-
nancy in LAM is associated with an increased incidence of
pneumothorax.14 Although there is no firm evidence about
the relationship between LAM and pregnancy, women with
LAM are frequently advised to avoid pregnancy as it may
exacerbate the disease. It is therefore important to know
both the effect of pregnancy on LAM progression and the
effect of LAM on pregnancy so that women with LAM
considering pregnancy can make informed decisions.
To address these questions we used two international
registries of LAM patients to survey women with LAM about
their pregnancy experiences. The following questions
guided the research: Did the diagnosis of LAM affect
a woman’s decision to attempt pregnancy? Does LAM affect
pregnancy outcome? And does pregnancy have an impact on
the natural progression of LAM?Methods
After the University of Toronto and the Trent multi-centre
research ethics committees granted institutional research
ethics board approval we mailed a questionnaire to women
registered with the U.S. LAM Foundation (nZ 448) and U.K.
LAM Action (nZ 59). Informed consent was assumed by
return of the completed questionnaire. Non-respondents
were mailed a second survey, followed 3 months later by
a postcard reminder.
The survey included questions on date of birth, date of
diagnosis with LAM, age of first LAM symptoms, and whether
the respondent had a diagnosis of tuberous sclerosis
complex (TSC). We gathered further information pertaining
to LAM symptoms and complications, obtained a pregnancy
history and collected health outcome data as detailed
below.
 Pulmonary function: LAM Foundation participants
were asked to send copies of their most recent
pulmonary function tests (PFTs), including spirometry,
lung volumes and diffusing capacity where available.
 Activities of daily living: The Functional Performance
Inventory (FPI) is a reliable indicator of functionalperformance status and is validated in patients whose
activity is limited by chronic lung disease.15 The FPI
assesses several domains including physical exercise,
ability to maintain the household, and body care scores
are from 1 to 4, where 1Z ‘no difficulty’ and 4Z ‘don’t
do because of health’.
 Psychological functioning: The Psychological General
Well-Being Schedule (GWB) measures overall sense of
well-being and has six subscales: anxiety, depression,
vitality, self-control, general health, and positive
well-being over the previous month.16 Higher scores
represent better psychological health (less distress).
Two questions pertaining to ‘general health’ were
omitted because they did not apply to women with
LAM.
 Overall quality of life (QOL) was measured by using
a Visual Analogue Scale. Participants were asked to
indicate their QOL over the preceding 4 weeks by
placing a mark on a 10-cm line at the point that best
depicts their rating. This measure has been used in prior
health outcomes research to evaluate subjective QOL.17
 Dyspnoea was assessed by asking respondents about
their frequency of shortness of breath (never, almost
never, a little of the time, some of the time, a good bit
of the time, most of the time and all of the time, scored
1e 7).18
 Fatigue was assessed by the use of a 10 cm visual
analogue scale (1Z most fatigued/tired, 10Z least
fatigued/tired).
Statistical analysis
To assess the effect of LAM on pregnancy, we compared the
pregnancy outcomes (full term or premature birth,
miscarriage or therapeutic abortion) of the first three
pregnancies for respondents who had ever been pregnant.
These were categorised into three groups: women diag-
nosed prior to pregnancy, diagnosed during pregnancy, or
diagnosed after pregnancy. We also determined the
percentage of women in each group who had symptoms
suggestive of LAM, namely, pneumothorax, chylothorax or
breathlessness during a pregnancy.
To assess the effect of pregnancy on LAM, we compared
longer term health outcomes for four groups: women
diagnosed prior to pregnancy, women diagnosed during
pregnancy, women diagnosed after pregnancy and women
who had never been pregnant. These comparisons included
continuous variables: the mean values for GWB, depression
and anxiety subscales, dyspnoea and fatigue scores, QOL
and FPI. Other comparisons included the percentage ever
on a waiting list for lung transplant, ever had a lung
transplant, pneumothorax, chylothorax or use of supple-
mentary oxygen. To ascertain whether differences in
pregnancy outcomes could be explained by other
confounders, we determined the patients’ age at the time
of pregnancy and socioeconomic status. Since only one
woman was a current smoker, we did not compare smoking
status.
Due to small numbers of pulmonary function test results,
we combined the mean values between women diagnosed
prior to or during pregnancy vs. those diagnosed after
Table 2 Pregnancy outcomes by timing of diagnosis of
LAM.
Outcomes Diagnosis
before
Diagnosis
during
Diagnosis
after
P-valuea
768 M.M. Cohen et al.pregnancy or never pregnant. Chi-squared test, ANOVA
(controlling for age and history of pneumothorax) were
used to test for statistical significance using SAS version 8.0.
Results
We received 338 questions, of which 10 were incomplete
leaving 328 usable questionnaires (overall response rate
70.5%). Most respondents were from the US (63.7%), 14.9%
were from the UK, 6.7% were from Canada and 14.6% from
other countries. Of the respondents, 51 (16.0%) had been
diagnosed with TSC. Thirty women had been on a waiting
list for transplant and 10 were post transplant.
Never pregnant group
One hundred and twenty three women (37.3%) had never
been pregnant. Of these, 22% had no partner, 31% did not
want children or did not want children yet. A further 8.2%
had not become pregnant despite trying to conceive (Table
1). In total, 55% of the women without children avoided
pregnancy because of concerns about the potential impact
of a pregnancy on LAM: either because a health care
professional had advised them against pregnancy (25%) or
because they were concerned that a pregnancy would
worsen their LAM symptoms (30%). A further 3% avoided
pregnancy because they were worried about passing
tuberous sclerosis on to their child.
Pregnancy group
Two hundred and five (62.6%) had been pregnant at least
once (mean 1.8 pregnancies, range 1e8). Twenty-three
women (12.4%) wanted additional children, but only three
(1.6%) actually planned on having more children. Two
hundred and four women provided information about their
first five pregnancies (nZ 373 pregnancies); all except two
had three pregnancies or fewer. Most women (nZ 178,Table 1 Reasons for not having a pregnancy (nZ 123).
Reason N %a % for women
with partner
No partner 27 22.1 e
Does not want
children/not ready
to have children
38 31.1 40.0
Unable to have
children despite trying
10 8.2 10.5
Unable to have
children due to sterilisation
12 9.8 12.6
Afraid to have
children due to LAM
37 30.3 38.9
Advised by health
care professional
not to get pregnant
31 25.4 32.6
Concerned about
inheritance of TSC
4 3.3 4.2
a Percentages do not add to100% as multiple responses were
allowed.nZ 346 pregnancies) were diagnosed with LAM more than
a year after completing their pregnancies. Fifteen women
were diagnosed with LAM during a pregnancy (nZ 15
pregnancies) and 12 women embarked on 15 pregnancies
after they were diagnosed with LAM.
Effects of LAM on pregnancy
Pregnancy outcomes are listed in Table 2. Overall patients
diagnosed with LAM during pregnancy had a worse preg-
nancy outcome, with significantly more premature births
and miscarriages (53%, nZ 8) than those diagnosed before
pregnancy (20%, nZ 3) or after (15%, nZ 50). More women
with an existing or emerging diagnosis of LAM during preg-
nancy had their pregnancies terminated (17%, nZ 5)
compared with women diagnosed after pregnancy (7%,
nZ 24).
A diagnosis of LAM during pregnancy was associated not
only with a worse obstetric outcome, but also with
increased maternal respiratory complications: significantly
more of the women whose LAM was diagnosed during
pregnancy suffered breathlessness, pneumothorax or chy-
lothorax than those whose LAM was diagnosed before or
after pregnancy (Table 2). Of note, 5% of women who were
diagnosed with LAM more than a year after their last
pregnancy had a pneumothorax during a pregnancy
implying that they may have already had LAM but the
diagnosis was delayed.
Participants who were diagnosed with LAM after preg-
nancy were on average older than the other women at time
of the survey (p < 0.0001) but were significantly younger
(24.9 vs. 28.7e29.6 years) at the time of their first preg-
nancy (p < 0.0001).pregnancy pregnancy pregnancy
nZ 15 nZ 15 nZ 346
N (%) N (%) N (%)
Obstetric
Full term birth 9 (60.0) 5 (33.3) 254 (75.8) 0.001
Premature birth 2 (13.3) 7 (46.7) 20 (6.0) 0.0001
Miscarriage 1 (6.7) 1 (6.7) 30 (9.0) 0.84
Termination of
Pregnancy
3 (20.0) 2 (13.3) 24 (7.2) 0.25
Other birth
outcomesb
0 0 7 (2.0)
% premature
births among
live born
18.1 58.3 7.3
Respiratory
Pneumothorax 4 (26.7) 10 (66.7) 18 (5.2) 0.0001
Breathlessness 1 (6.7) 10 (66.7) 25 (7.2) 0.0001
Other respiratory
problems
4 (26.7) 1 (6.7) 9 (2.6) 0.001
a ANOVA.
b Four tubal pregnancies, three not stated.
Pregnancy experiences in LAM 769The time since diagnosis did not vary between groups at
the time of analysis (pZ 0.69). There were no significant
differences in socioeconomic status between women who
were diagnosed prior to pregnancy, during pregnancy, after
pregnancy or with no pregnancy. Women who had never
been pregnant were less likely to be married (p < 0.0006).
Effect of pregnancy on LAM
Given the hypothesis that LAM is a hormone-dependent
condition we investigated whether pregnancies affected
the natural history of LAM (Table 3). There were no
differences between the four groups for the FPI subscales
body care, household maintenance or exercise, mean
dyspnoea score, GWB total score, depression, anxiety or
mean fatigue scores. Mean QOL scores were 7.2, 7.3, 7.3
and 7.4 for the four groups (pZ 0.92).
The differences in proportions of women in the four
groups who had ever been on a waiting list for transplant
were not statistically significant. There were also no
differences in the percentage of women who ever had
a pneumothorax, chylothorax or were currently using
supplemental oxygen. More women who were diagnosedTable 3 Health outcomes and socio economic status by diagno
Diagnosis
before
pregnancy
Diag
duri
preg
nZ 12 nZ
Mean (SD) Mea
Age at time of survey (years) 37.1 (7.6) 39.0
Age at first pregnancy (years) 31.4 (7.3) 28.9
Time since diagnosis (years) 6.6 (4.6) 7.4
GWB total score
(range 0e108, lowZ more distress)
71.6 (11) 64.7
Anxiety (range 0e28, lowZ more anxious) 17.3 (2.4) 17.0
Depression (range 0e22
lowZ more depressed)
16.3 (3.5) 13.5
Dyspnoea score (1Z low, 7Z high) 3.8 (1.5) 4.3
Fatigue score (1Z low, 10Z high) 4.6 (2.6) 3.4
FPI body (1Z low, 4Z high) 1.33 (0.49) 1.27
FPI household (1Z low, 4Z high) 1.73 (0.52) 1.77
FPI exercise (1Z low, 4Z high) 1.88 (0.55) 1.93
Quality of life (1Z low 10Z high) 7.22 (2.0) 7.23
N (%) N (%
Total household income <$40,000 US or
£ 40,000 pa
4 (33.3) 9 (6
High school education or less 3 (25.0) 4 (2
Currently married 11 (91.7) 12 (
Currently taking progesterone 2 (16.7) 9 (6
Supplementary oxygen 3 (25.0) 6 (4
Post transplant 0 0
Ever on transplant waiting list 1 (8.3) 3 (2
Ever had pneumothorax or chylothorax 9 (75.0) 11 (
NA: not applicable; FPI: Functional Performance Inventory; GWB: Ge
a ANOVA: between three pregnancy groups.
b ANOVA: between four groups.
c Chi-square or Fisher’s exact test three groups.
d Chi-square or Fisher’s exact test four groups.during pregnancy were subsequently treated with proges-
terone (pZ 0.002) than women in the other groups.
Pulmonary function tests
PFT results were received from 117 (36%) of women (Table
4). Not all women had test results for all PFT parameters.
Compared to women who had been diagnosed after preg-
nancy, women who had been diagnosed before or during
pregnancy had poorer lung function, with lower FEV1, FVC
and DLCO. There were also borderline differences in FEV1/
FVC (pZ 0.06) and RV/TLC (pZ 0.08).
Lung function in women who had never been pregnant
was similar to lung function in women who were diagnosed
with LAM after pregnancy on all parameters except the
never pregnant group had a higher FEV1/FVC ratio
(pZ 0.003).
Discussion
In this retrospective study of pregnancy and LAM over
a third of women did not have children, compared to 15% in
the general population.19 The majority of women basedsis timing and pregnancy status.
nosis
ng
nancy
Diagnosis
after
pregnancy
P-valuea Never
pregnant
P-valueb
15 nZ 177 nZ 123
n (SD) Mean (SD) Mean (SD)
(4.5) 48.7 (9.7) <0.0001 44.5 <0.0001
(4.7) 25.1 (5.3) <0.0001 NA NA
(3.7) 6.6 (5.9) 0.69 6.1 (5.3) 0.77
(14) 70.0(13) 0.29 70.9 (13) 0.37
(2.5) 17.4 (2.4) 0.87 17.3 (2.6) 0.96
(4.2) 15.3 (4.1) 0.15 15.4 (3.7) 0.25
(1.4) 4.3 (1.4) 0.54 4.2 (1.5) 0.69
(2.0) 4.2 (2.4) 0.38 4.4 (2.6) 0.44
(0.45) 1.36 (0.54) 0.82 1.40 (5.7) 0.81
(0.59) 1.80 (0.69) 0.93 1.79 (0.75) 0.99
(0.67) 2.19 (0.78) 0.23 2.10 (0.81) 0.36
(1.5) 7.35 (2.2) 0.78 7.34 (2.2) 0.92
) N (%) c N (%) d
0.0) 71 (40.1) 0.28 46 (37.3) 0.38
6.7) 51 (28.8) 0.95 22 (17.9) 0.19
80.0) 128 (72.3) 0.29 65 (52.8) 0.0006
0.0) 41 (23.2) 0.006 47 (38.2) 0.0016
0.0) 57 (32.2) 0.71 43 (35.0) 0.82
6 (3.4) 0.62 4 (3.2) 0.81
0.0) 16 (9.0) 0.38 14 (11.4) 0.57
73.3) 110 (62.1) 0.48 86 (70.0) 0.42
neral Well-being Score.
Table 4 Most recent pulmonary function tests at time of survey by pregnancy status and timing of diagnosis of LAM.
PFT Diagnosis before
or during pregnancy
Diagnosis
after pregnancy
P-valuea Never pregnant P-valueb
nZ 12 nZ 65 nZ 40
Mean (SD) Mean (SD) Mean (SD)
FEV1% predicted 49.9 (19.7) 68.3 (26.3) 0.006 68.6 (28) 0.12
FVC % predicted 75.8 (15.6) 87.9 (20.1) 0.038 78.5 (22) 0.44
FEV/FVC % 53.6 (18) 59.2 (15) 0.06 67.1 (16) 0.003
TLC % predicted 98.6 (12.1) 99.8 (15.2) 0.51 92.8 (15) 0.37
RV % predicted 139.5 (77) 126.2 (38) 0.22 110.1 (20) 0.08
RV/TLC % 45.1 (15) 43.2 (11) 0.08 40.8 (11) 0.17
DLCO sb % predicted 41.2 (23) 66.1 (25) 0.004 64.4 (23) 0.10
a ANOVA controlling for age and history of pneumothorax (diagnosis before or during pregnancy vs. diagnosis after pregnancy).
b ANOVA controlling for age and history of pneumothorax (diagnosis after pregnancy vs. never pregnant).
770 M.M. Cohen et al.their decision not to have children on their disease, either
out of concern that pregnancy would worsen LAM, because
they were concerned about passing on TSC to their
offspring, or because they had been advised by a health
care professional not to get pregnant because of LAM. Ten
percent of women had undergone sterilisation. Abortion
rates were higher in women who were diagnosed with LAM
prior to or during pregnancy than in women who became
pregnant before they were diagnosed with LAM; suggesting
that the extra abortions may have been performed on the
account of LAM, possibly due to concerns about maternal
health or pregnancy outcome.
In addition to the women who decided to remain
childless, a further 8% of women were unable to conceive
despite trying (compared to 4% in the general pop-
ulation).19 This is in keeping with previously published
data, which demonstrated that women with LAM were less
fertile and had fewer children.20 The reason for the lower
fertility is not known, but chronic ill health may hinder
conception and specific to LAM, progesterone treatment is
contraceptive.
Sixty two percent of women studied had been pregnant
at least once. Most of these pregnancies (88%) occurred at
least 1 year before the diagnosis of LAM. Pregnancy
outcomes in this group were good, with only 5% of preg-
nancies ending in miscarriage or still birth and only 5%
delivering prematurely, even though a proportion of these
women probably did have LAM at the time of their preg-
nancy (almost 5% of these pregnancies were complicated by
development of a pneumothorax but LAM was not formally
diagnosed until at least 1 year later).
Women who were diagnosed during pregnancy had the
worst outcomes, with almost half of the pregnancies ending
in premature delivery. It is not known whether these
premature births were spontaneous or whether delivery
was initiated by the obstetricians because of concerns
about the foetus’ well-being or deteriorating health of the
mother.
These findings are in keeping with early reports that
describe the dramatic onset of LAM-associated symptoms
during pregnancy. For example, Brunelli et al.11 describe
a 26 year old woman in the 35th week of pregnancy pre-
senting with massive bilateral chylothorax leading to anemergency caesarean section. Urban et al. reviewed 69
LAM patients, 75% of whom had at least one pregnancy. The
onset of pulmonary symptoms occurred in 20% of these
pregnancies, and marked exacerbation of existing LAM was
observed in two patients during pregnancy.21 Johnson and
Tattersfield evaluated 50 LAM patients of whom 28 had
been pregnant and 27 had children. There was a higher
rate of pneumothorax and chylous effusions during preg-
nancy than at other times and seven patients (14%) devel-
oped their first symptoms of LAM during, or immediately
after a pregnancy.14 A study by Mitchell et al. examined 25
women with TSC and LAM who had 61 pregnancies; 4.9% had
a pneumothorax during a pregnancy (all in the third
trimester).22 In a comprehensive review article, Sullivan
notes that ‘‘it is not clear whether pregnancy caused the
acute progression of LAM or whether the haemodynamic
and ventilatory perturbations associated with pregnancy
simply brought out the symptoms of LAM that would
otherwise not have been noticed until the disease pro-
gressed further’’.23 It is also possible that LAM diagnosed
during pregnancy may be a marker of more aggressive
disease, as radiological and invasive procedures would
probably have been delayed until after delivery for milder
symptoms. On the other hand pregnancy may trigger a LAM
flare in some women, although it is not known what
predisposes to such an adverse response. One possible
explanation is the variable expression of oestrogen and
progesterone receptors in LAM tissue24 which could account
for some women being more sensitive to hormonal changes
than others.
Women who were diagnosed with LAM prior to pregnancy
were at intermediate risk both for obstetric and respiratory
complications compared to those women who were diag-
nosed whilst they were pregnant or those who completed
their pregnancies prior to being diagnosed. The more
favourable outcome compared to those with new active
disease during pregnancy may be a reflection of disease
severity. It is conceivable that women with milder disease
are more likely to contemplate pregnancy, be more fertile
and have a more favourable course during pregnancy
whereas women with a more severe disease who may have
poor pregnancy outcomes either avoid pregnancy or are less
fertile.
Pregnancy experiences in LAM 771However it appears to be true for both groups that an
established or emergent diagnosis of LAM during pregnancy
may have a long lasting effect. On average, women with
existing or emerging LAM who embarked on pregnancy had
significantly poorer lung function (lower FEV1, FVC and
DLCO) than women who had children earlier and developed
LAM later in life. Women who developed a pneumothorax
during pregnancy but were not diagnosed formally with LAM
(nZ 18) had similar health outcomes, including lung func-
tion, as those who were diagnosed during pregnancy (data
not shown). On the other hand women who were pregnant
before a diagnosis of LAM had similar lung function to those
women who had never been pregnant. These observations
remained valid after correction for age, disease duration
and history of pneumothorax. Our findings, although based
on small numbers, support the perception that pregnancy
adversely affects the natural history of LAM. Consistent
with this, a previous study of 57 patients found that patients
who had been pregnant reached MRC grade 3 dyspnoea
sooner than those who had never been pregnant.10
Women diagnosed before or around the time of preg-
nancy were on average 5 years older during their first
pregnancy than those diagnosed more than 2 years after
the birth of their child. A possible explanation for this
observation may be that women who did not develop
symptoms when faced with the hormonal challenge of
pregnancy have a milder or less reactive disease phenotype
and that the observed difference in respiratory function
cannot solely be attributed to pregnancy.
In addition to counselling women with LAM about the
possible effect pregnancy may have on their respiratory
health, their emotional well-being should also be taken into
account. Studies of women with fertility problems have
shown high rates of depression, anxiety and difficulties with
their partners.25,26 However, in our study there was no
difference in the measures of quality of life, general well-
being, depression or anxiety between women with or
without children.
Although this is the largest study to address pregnancy in
LAM our findings are still based on a relatively small number of
patients. Given this caveat, our data suggests that if LAM
remains stable during pregnancy, miscarriage rates are not
increased and premature births are comparable to those in
the general population. However, whilst women with LAM can
have uncomplicated pregnancies (60% of pregnancies in
women with existing LAM went to term): respiratory compli-
cations and adverse pregnancy outcomes are more common in
patients who flare during pregnancy or in those who are first
diagnosed during pregnancy, which may be a sign of a more
aggressive disease. Furthermore pregnancy may adversely
effect lung function long term although this does not appear
to translate into worse dyspnoea or quality of life.
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